TY - JOUR
T1 - Epithelial-mesenchymal Transition Factor and Its Association with Mammographic Density and Breast Cancer Prognosis
AU - Kim, Eun Young
AU - Ahn, Sangjeong
N1 - Publisher Copyright:
© 2023 International Institute of Anticancer Research. All rights reserved.
PY - 2023/5
Y1 - 2023/5
N2 - Background/Aim: The tumor microenvironment influences tumor progression, invasion, and metastasis. This study determined the expression levels of epithelialmesenchymal transition (EMT) factors according to zone and their correlation with mammographic breast density and investigated the prognostic value of EMT factors. Patients and Methods: The clinical and pathological data of invasive carcinoma and ductal carcinoma in situ were reviewed. Primary breast tissue samples were evaluated using immunohistochemistry (IHC) staining of the EMTassociated markers, including a-SMA, vimentin, MMP-9, and CD34. The expression levels were analyzed in three areas: the tumor center, interface, and distal zones. EMT factors were correlated with mammographic breast density and oncologic outcomes. Results: An overall EMT phenotype conversion from positive to negative was seen in 55.7% of a-SMA- and 34.4% of MMP-9-positive cells between the tumor center and interface zones, which was significantly different (p<0.05). Most changes in EMT expression from the center to the distal zone were from positive to negative, but 23.0% of CD34-expressing cells showed negative to positive conversion. The proportion of a-SMA, vimentin, and MMP-9 expression was higher in the non-dense breast group compared to the dense breast group in the interface and distal zones (p<0.05). CD34 expression in the distal zone was an independent favorable prognostic factor for disease-free survival (p=0.039). Conclusion: The differential expression of EMT markers in each zone suggests heterogeneous cancer cell populations within each zone of breast cancer. EMT factor expression can also interplay between breast density stroma and geographical tumor zone.
AB - Background/Aim: The tumor microenvironment influences tumor progression, invasion, and metastasis. This study determined the expression levels of epithelialmesenchymal transition (EMT) factors according to zone and their correlation with mammographic breast density and investigated the prognostic value of EMT factors. Patients and Methods: The clinical and pathological data of invasive carcinoma and ductal carcinoma in situ were reviewed. Primary breast tissue samples were evaluated using immunohistochemistry (IHC) staining of the EMTassociated markers, including a-SMA, vimentin, MMP-9, and CD34. The expression levels were analyzed in three areas: the tumor center, interface, and distal zones. EMT factors were correlated with mammographic breast density and oncologic outcomes. Results: An overall EMT phenotype conversion from positive to negative was seen in 55.7% of a-SMA- and 34.4% of MMP-9-positive cells between the tumor center and interface zones, which was significantly different (p<0.05). Most changes in EMT expression from the center to the distal zone were from positive to negative, but 23.0% of CD34-expressing cells showed negative to positive conversion. The proportion of a-SMA, vimentin, and MMP-9 expression was higher in the non-dense breast group compared to the dense breast group in the interface and distal zones (p<0.05). CD34 expression in the distal zone was an independent favorable prognostic factor for disease-free survival (p=0.039). Conclusion: The differential expression of EMT markers in each zone suggests heterogeneous cancer cell populations within each zone of breast cancer. EMT factor expression can also interplay between breast density stroma and geographical tumor zone.
KW - Breast carcinoma
KW - epithelial mesenchymal transition
KW - mammographic breast density
KW - prognosis
UR - https://www.scopus.com/pages/publications/85153900387
U2 - 10.21873/anticanres.16392
DO - 10.21873/anticanres.16392
M3 - Article
C2 - 37097661
AN - SCOPUS:85153900387
SN - 0250-7005
VL - 43
SP - 2281
EP - 2292
JO - Anticancer Research
JF - Anticancer Research
IS - 5
ER -